Prelica CR 82.5 mg (Tablet (Controlled Release))

Indications

• Neuropathic pain associated with diabetic peripheral neuropathy (DPN)
• Postherpetic neuralgia (PHN)
• Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older
• Fibromyalgia
• Neuropathic pain associated with spinal cord injury

Pharmacology

• Structural derivative of inhibitory neurotransmitter gamma-aminobutyric acid (GABA)
• Binds with high affinity to the alpha2-delta site in central nervous system tissues
• Anti-nociceptive and antiseizure effects

Dosage

• Maximum recommended dose of Pregabalin is 100 mg three times a day (300 mg/day) for DPN
• Recommended dose of Pregabalin is 75 to 150 mg two times a day or 50 to 100 mg three times a day for PHN
• Recommended dose of Pregabalin is 300 to 450 mg/day for fibromyalgia
• Recommended dose range of Pregabalin is 150 to 600 mg/day for spinal cord injury

Administration

• Oral route of administration
• Can be taken with or without food
• Pregabalin CR tablet should be administered after an evening meal
• Swallowed whole and should not be split, crushed or chewed

Interaction

• Unlikely to be involved in significant pharmacokinetic drug interactions

Contraindications

• Contraindicated in patients with known hypersensitivity to Pregabalin or any of its components

Side Effects

• Most common side effects in adults: dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, thinking abnormal
• Most common side effects in pediatric patients for the treatment of partial onset seizures: increased weight, increased appetite

Pregnancy & Lactation

• No adequate and well-controlled studies in pregnant women
• Small amounts detected in the milk of lactating women
• Breastfeeding not recommended during treatment

Precautions & Warnings

• Angioedema can occur and may be associated with life threatening respiratory compromise
• Discontinue immediately in case of hypersensitivity reactions
• Increase in risk of suicidal thoughts or behavior
• May cause dizziness and somnolence, impairing ability to drive or operate machinery
• Increased seizure frequency or other adverse reactions may occur if rapidly discontinued
• May cause peripheral edema
• Caution should be exercised when coadministering with thiazolidinedione antidiabetic agents

Use in Special Populations

• Safety and effectiveness in pediatric patients have not been established
• Safety and effectiveness of extended-release tablet in pediatric patients have not been established

Overdose Effects

• Signs and symptoms: reduced consciousness, depression/anxiety, confusional state, agitation, restlessness, seizures, heart block
• No specific antidote

Therapeutic Class

• Adjunct anti-epileptic drugs
• Primary anti-epileptic drugs

Storage Conditions

• Keep in a cool & dry place (below 30°C)
• Protected from light & moisture
• Keep out of the reach of children

Chemical Structure

• Molecular Formula: C8H17NO2

Common Questions about Prelica CR 82.5 mg Tablet

• Considered first-line of treatment for neurotic pain, shingles, seizures and fibromyalgia
• To be taken till improvement in health conditions
• Should be taken in prescribed dosage after food
• Should be kept in cool dry place in its original packaging, unreachable to children and pets
• Works in different ways for different diseases

Related Brands

• Prelica CR 165 mg (Tablet (Controlled Release)) - radiant-pharmaceuticals-ltd
• Prebalin CR 82.5 mg (Tablet (Extended Release)) - general-pharmaceuticals-ltd
• Prebalin CR 165 mg (Tablet (Extended Release)) - general-pharmaceuticals-ltd
• Lyca CR 82.5 mg (Tablet (Controlled Release)) - delta-pharma-ltd
• Lyca CR 165 mg (Tablet (Controlled Release)) - delta-pharma-ltd